Results 91 to 100 of about 6,494 (198)

Advances in boron neutron capture therapy for cutaneous malignancies

Pifu-xingbing zhenliaoxue zazhi
As an effective therapeutic strategy for malignant neoplasms, boron neutron capture therapy(BNCT)has demonstrated promising clinical outcomes across various cutaneous malignancies.
HUANG Cui'er, LIU Wenqi, LI Changxing
doaj   +1 more source

Accelerator-based BNCT with Medium- to High-Energy Proton Beams

, 2009
The realization of the accelerator-based boron neutron capture therapy (BNCT) will greatly contribute to the development of BNCT. To solve some difficulties in realizing the accelerator-based BNCT in clinical use, we have proposed the accelerator-based ...
Yonai, Shunsuke, 553159, 米内 俊祐, 553160   +3 more
core  

Clinical application of boron neutron capture therapy for cancer treatment: A systematic review

Precision Radiation Oncology
Boron neutron capture therapy (BNCT) combines boron drug delivery and heavy‐ion therapy. The key factors in the application of BNCT are high‐quality neutron beams and boron‐containing compounds.
Ling Zhou, Yuming Chen, Meng Peng, Xiumao Yin, Huanqing Liang, Jieming Mo, Wan Zhang, Zhigang Liu   +7 more
doaj   +1 more source

Comparison of lifetime attributable risk of post-irradiation secondary cancer of boron neutron capture therapy, proton beam therapy, and X-ray therapy for pediatric and adolescent and young adult patients

Clinical and Translational Radiation Oncology
Background and purpose: This study aimed to compare the post-irradiation secondary cancer rates of boron neutron capture therapy (BNCT), proton beam therapy (PBT), and X-ray therapy (XT) in pediatric and Adolescent and Young Adult (AYA) patients with ...
Shunsuke Suzuki, Shintaro Shiba, Hiroki Tanaka, Masashi Yamanaka, Kazuki Matsumoto, Koichi Tokuuye, Motoko Omura   +6 more
doaj   +1 more source

Dose calculation in Sprague-Dawley rats affected by limb osteosarcoma for BNCT in vivo tests at the TRIGA reactor in Pavia

, 2013
Osteosarcoma is the most common non-hematologic primary cancer that affects bones. The patients are typically very young, being the first incident peak between 10 and 20 years old.
S. J. Gonzales, BORTOLUSSI, SILVA, CLERICI, ANNA MARIA, PROTTI, NICOLETTA, L. Ciani, FERRARI, CINZIA, L. Panza, ZONTA, CECILIA, S. Ristori, ALTIERI, SAVERIO, R. O. Farìas, BRUSCHI, PIERO, CANSOLINO, LAURA, POSTUMA, IAN, BALLARINI, FRANCESCA   +14 more
core  

Boron neutron capture therapy (BNCT) for newly-diagnosed glioblastoma : Comparison of clinical results obtained with BNCT and conventional treatment [PDF]

, 2014
The purpose of this study was to evaluate the clinical outcome of boron neutron capture therapy (BNCT) and conventional treatment in patients with newly diagnosed glioblastoma.
カゲジ, テルヨシ, Kageji, Teruyoshi, 60145315, 70294684, 80547993, 永廣, 信治, Mizobuchi, Yoshifumi, Kumada, Hiroaki, 23218/profile-ja.html, Matsuzaki, Kazuhito, 393, ナカガワ, ヨシノブ, Nagahiro, Shinji, ナガヒロ, シンジ, 溝渕, 佳史, マツザキ, カズヒト, ミゾブチ, ヨシフミ, Nakagawa, Yoshinobu, 538, 影治, 照喜, 1638, クマダ, ヒロアキ   +21 more
core  

Enhanced blood boron concentration estimation for BPA-F mediated BNCT

, 2004
The blood boron concentration regulates directly the BNCT irradiation time in which the prescribed dose to the patient is delivered. Therefore a proper estimation of the blood boron concentration for the treatment field based on the measured blood ...
Savolainen, S., Seppälä, T., Auterinen, Iiro, Kortesniemi, Mika   +3 more
core   +1 more source

Manganese-enriched nanoboron agent amplifies BNCT efficacy via pyroptosis-mediated immune activation and STING pathway synergy​

Journal of Nanobiotechnology
Boron Neutron Capture Therapy (BNCT) offers selective tumor cell ablation with minimal damage to normal tissues, but its efficacy is limited by therapy-induced immunosuppression and high intratumoral H2O2 levels, restricting synergy with immunotherapy ...
Zhicheng Zhang, Xiaoyan Sun, Yaxin Qin, Yufan Yang, Qi Dai, Xiaoyan Bao, Minoru Suzuki, Sheng Wang, Zai Yang, Zhifeng Li, Min Han, Donghang Xu, Qichun Wei   +12 more
doaj   +1 more source

closo-borane conjugated regulatory peptides retain high biological affinity: synthesis of closo-borane conjugated Tyr(3)-octreotate derivatives for BNCT

, 2008
Despite the improvements in cancer therapy during the past years, high-grade gliomas and many other types of cancer are still extremely resistant to current forms of therapy. Boron neutron capture therapy (BNCT) provides a promising way to destroy cancer
Reubi, Jean-C., Betzel, Thomas, Waser, Beatrice, Roesch, Frank, Hess, Tobias   +4 more
core   +1 more source

Targeting SLC7A5 in lung squamous cell carcinoma: implications for cancer metabolism shift and boron neutron capture therapy resistance

Oncogenesis
Squamous cell carcinoma (SCC) poses a significant global health challenge due to the lack of effective treatments. Boron neutron capture therapy (BNCT), a targeted particle therapy, has shown promising results in various cancers. SLC7A5, a transporter of
Yen-Ju Lin, Yu-Cheng Wu, Yu-Jui Liu, Wei-Chen Yeh, Yi-Chen Huang, Shen-Ao Zhang, Alvin Chen, Ming-Yi Zheng, Hong-Ming Liu, Fong-In Chou, Shien-Tung Pan, Min-Yuan Chou, Yu-Ting Chou   +12 more
doaj   +1 more source